Parenteral Nutrition Does Not Stimulate Tumor Proliferation in Malnourished Gastric Cancer Patients

Abstract

Background: The present study evaluated the effects of preoperative parenteral nutrition (PN) on tumor cell proliferation in malnourished gastric cancer patients. Methods: Twenty malnourished patients affected by gastric cancer were randomized to receive the standard hospital oral diet (control group) or the standard hospital oral diet plus PN (PN group; 0.2 g/kg/d of nitrogen and 30 nonprotein kcal/kg/d). Samples of tumor tissue and surrounding health mucosa were taken by endoscopic biopsies and from the operative specimen, immediately after resection. Tissues were sent for histologic examination and prepared for flow cytometry and for the measurement of the uptake of bromodeoxyuridine (BduR) by cells after in vitro exposure to the agent. The BduR uptake is largely used to assess the proportion of cells actively synthesizing DNA and is one of the principle methods used to measure tumor proliferation. Results: In the PN group, the mean percentage of tumor cells incorporating BduR was 2.51%± 1.7% in the endoscopic samples and 1.52% ± 0.8% in the operative specimens (p = .2). In the normal mucosa, the mean percentage of cells incorporating BduR was 2.24% ± 1.8% and 1.13%± 1.1%, respectively (p = .1). In the control group, the percentage of cells incorporating BduR in the normal mucosa was 1.26% ± 1.1% at endoscopy and 0.41% ± 0.3% at surgery (p = .2), whereas the percentage of cells incorporating BduR in the tumor tissue was 1.41% ± 1.2% at endoscopy and 0.48% ± 0.6% at surgery (p = .2). The percentage of S-phase cells documented by flow cytometry in the PN group was: in the tumor, 6.6% ± 2.9% in the endoscopic samples and 5.7% ± 2.5% in the operative specimens (p = .6); in the normal mucosa, 5.8% ± 2.5% at endoscopy and 5.4% ± 0.9% at surgery (p = .7). In the control group, the percentage of proliferating cells measured by flow cytometry was 4.9% ± 3.2% in the normal mucosa taken by endoscopic biopsy and 5.3% ± 1.4% in the normal mucosa taken from the operative specimens (p = .8), whereas it was 11.4% ± 7.2% in the tumor taken with endoscopic biopsy and 9.7% ± 4% in the tumor tissue taken from the surgical specimens (p = .7). Conclusions: The present study suggests that PN does not stimulate tumor proliferation in malnourished patients affected by gastric cancer.

Tumor cell proliferation was evaluated in 20 malnourished gastric cancer patients randomized to receive the oral hospital standard diet (control group) or the oral standard hospital diet associated with parenteral nutrition (PN) support (treatment group). Tumor proliferation was assessed before and after nutrition treatment using flow cytometry and the measurement of the uptake of bromodeoxyuridine (BduR) by cells. The mean percentage of tumor cells incorporating BduR was similar in the control and in the treatment groups, as well as the percentage of S-phase cells documented by flow cytometry. The present study suggests that PN does not stimulate tumor proliferation in malnourished patients affected by gastric cancer.

Get full access to this article

View all access options for this article.

References

Martindale RG, Maerz LL. Management of perioperative nutrition support. Curr Opin Crit Care. 2006 ;12:290– 294.

Bellantone R, Doglietto GB, Bossola M, et al. Preoperative parenteral nutrition in the high risk surgical patient. JPEN J Parenter Enteral Nutr. 1988;12:195– 197.

Cameron IL, Ackley WJ, Rogers W. Response of hepatoma-bearing rats to total parenteral nutrition and to ad libitum feeding. J Surg Res. 1977;23:189– 195.

Popp MB, Wagner SC, Brito OJ. Host and tumor responses to increasing levels of intravenous nutritional support. Surgery. 1983 ;94:300– 308.

Eden E, Lindmark L, Lundholm K. Role of whole-body lipids and nitrogen as limiting factors for survival in tumor-bearing mice with anorexia and cachexia. Cancer Res. 1983 ;43:3707– 3711.

Sauer LA, Nagel WO, Dauchy RT, Miceli LA, Austin JE. Stimulation of tumor growth in adult rats in vivo during an acute fast. Cancer Res. 1986;46:3469– 3475.

Stragand J, Braunscheiger PG, Pollice AA, Schiffer LM. Cell kinetics alterations murine mammary tumors following fasting and re-feeding.Eur J Cancer. 1978;15:281– 286.

Torosian MH, Tsou KC, Daly JM. Alteration of tumor cell kinetics by pulse total parenteral nutrition. Cancer. 1984 ;53:1409– 1415.

Mullen JL, Buzby GP, Gertner MH, et al. Protein synthesis dynamics in human gastrointestinal malignancies. Surgery. 1980 ;87:331– 338.

10.

Ota DM, Nishioka K, Foulkes M, Grossie VB. Nutritional parameters affecting erythrocyte polyamine levels in cancer patients. J Clin Oncol. 1984;2:1157– 1164.

11.

Baron PL, Lawrence W Jr, Chaw WM, White FK, Banks WL Jr. Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer.Arch Surg. 1986;121:1282– 1286.

12.

Franchi F, Rossi Fanelli F, Seminara P, Cascino A, Barone C, Scucchi L. Cell kinetics of gastrointestinal tumors after different nutritional regimens (a preliminary report). J Clin Gastroenterol. 1991;13:313– 315.

13.

Westin T, Stein H, Niedobitek G, Lundholm K, Edstrom S. Tumor cytokinetic response to total parenteral nutrition in patients with head and neck cancer. Am J Clin Nutr. 1991 ;153:764– 768.

14.

Dionigi P, Jemos V, Cebrelli T, Ferrari A, Beritti F, Mazzini G. Preoperative nutritional support and tumor cell kinetics in malnourished patients with gastric cancer. Clin Nutr. 1991 ;10:77– 84.

15.

Heys SD, Park KG, McNurlan MA, et al. Stimulation of protein synthesis in human tumors by parenteral nutrition: evidence for modulation of tumor growth. Br J Surg. 1991 ;78:483– 487.

16.

Frank JL, Lawrence W, Banks WL, McKinnon JG, Shan WM, Collins JM. Modulation of cell kinetics in human cancer with total parenteral nutrition.Cancer. 1992;69:1858– 1864.

17.

Edstrom S, Westin T, Delle U, Lundhol K. Cell cycle distribution and ornithine decarboxylase activity in head and neck cancer in response to enteral nutrition. Eur J Cancer Clin Oncol. 1989 ;25:227– 232.

18.

Bozzetti F, Gavazzi C, Cozzaglio A, Costa A, Spinelli P, Viola G. Total parenteral nutrition and tumor growth in malnourished patients with gastric cancer. Tumori. 1999 ;85:163– 166.

19.

Lee KH, Lee JH, Kim SW, et al. Prognostic value of DNA flow cytometry in stomach cancer: a 5-year prospective study. Br J Cancer. 1999;79:1727– 1735.

20.

Begg AC, McNally NJ, Shrieve DC. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample.Cytometry. 1985;6:620– 626.

21.

Fogt F, Wan J, O'Hara C. Flow cytometry measurement of cell-cycle kinetics in rat Walker-256 carcinoma following in vivo and in vitro pulse labelling with bromodeoxyuridine. Cytometry. 1991 ;12:33– 41.

22.

Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine.Proc Natl Acad Sci USA. 1983 ;80:5573– 5577.

23.

Ohyama S, Yonemura Y, Miyazaki I. Prognostic value of S-phase fraction and DNA ploidy studied with in vivo administration of bromodeoxyuridine on human gastric cancer. Cancer. 1990 ;65:116– 121.

24.

Hoshino T, Nagashima T, Murovic JA. Proliferative potential of human meningiomas of the brain: a cell kinetics study with bromodeoxyuridine.Cancer. 1986;58:1466– 1472.

25.

Hemmer J. Rapid in vitro bromodeoxyuridine labelling method for monitoring of therapy response in solid tumors. Cytometry. 1990 ;11:603– 609.

26.

Riccardi A, Danova M, Wilson GD. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res. 1988 ;48:6238– 6245.

27.

Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers;1997 : 1021–1054.

28.

Teodori L, Trinca ML, Goehde W, et al. Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BduR) monoclonal antibody method: comparison with DNA flow cytometric data. Int J Cancer. 1990 ;45:995– 1001.

29.

Teodori L, Trinca ML, Salvati F, Berettoni L, Storniello G, Gohde W. Cellular heterogeneity of DNA/total protein content in human lung tumors, as determined by flow cytometry. Int J Cancer. 1992 ;50:845– 853.

30.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathol. 1965 ;64:31– 49.

31.

Darzynkiewics Z, Traganos F, Melamed MR. New cell-cycle compartments identified by multiparameter flow cytometry.Cytometry. 1980;1:98– 108.

32.

Mauro F, Teodori L, Shuman J, Goedhe W. Flow cytometry as a tool for the prognostic assessment of human neoplasia. Int J Radiat Oncol Biol Phys. 1986;12:605– 606.

33.

Morstyn G, Hsu MS, Kinsella T. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest. 1983 ;72:1844– 1850.

34.

Russo A, Gianni L, Kinsella TJ, et al. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.Cancer Res. 1984;44:1702– 1705.